Apyx Medical Earnings Call Transcripts
Fiscal Year 2026
-
AYON, a fully integrated surgical aesthetics system, is driving strong growth and market interest by consolidating multiple technologies and addressing new demand from GLP-1-induced skin laxity. The company is achieving operational efficiencies, expanding internationally, and expects 17%-19% revenue growth this year.
Fiscal Year 2025
-
Record Q4 revenue and strong AYON system adoption drove 35% year-over-year growth, with positive EBITDA and improved cash flow. 2026 guidance projects continued double-digit growth in surgical aesthetics, with plans for international expansion and further product enhancements.
-
Revenue grew 12% year-over-year to $12.9M, driven by the AYON launch and strong Surgical Aesthetics sales. Gross margin improved to 64.4%, and net loss narrowed significantly. Updated 2025 guidance reflects higher expectations for AYON, with cash expected to last through 2027.
-
GLP-1-driven demand is fueling growth in surgical aesthetics, with AON’s integrated platform delivering superior clinical outcomes, efficiency, and patient satisfaction. Surgeons report increased procedure volumes and strong interest in the upcoming power-assisted handpiece.
-
GLP-1 therapies are reshaping the aesthetics market, driving demand for skin tightening and surgical interventions. New product launches like AYON and strong Renuvion sales support raised financial guidance and global expansion, with a focus on surgeon partnerships and operational efficiency.
-
Q2 2025 revenue declined 6% year-over-year, but gross margin improved and net loss narrowed due to cost reductions. Strong demand for AYON and Renuvion, especially in new markets like China, led to raised 2025 revenue guidance. Cash position remains solid.
-
Q1 2025 revenue declined 8% year-over-year to $9.4M, but advanced energy sales grew 6% and gross margin improved to 60.1%. Cost controls reduced net loss and cash burn, and 2025 guidance was reaffirmed with the AYON launch expected in H2 pending FDA clearance.
Fiscal Year 2024
-
Q4 2024 revenue declined 3% year-over-year, but advanced energy sales grew 30% sequentially from Q3. Cost reductions and a direct offering improved the financial position, while 2025 guidance projects stable revenue and margins. Aion system launch is expected in H2 2025, pending FDA clearance.
-
Significant cost reductions and a strong cash position set the stage for the 2025 launch of the Aion system, which integrates advanced surgical body contouring technologies. The company targets EBITDA positivity in 2026 and plans aggressive domestic and international expansion, supported by innovative adoption programs.
-
Q3 revenue declined 4% year-over-year, with Advanced Energy down 6% and OEM up 3%. Major restructuring, cost reductions, and a $7M investment aim to extend runway and support new product launches, including the Aion system expected in H2 2025.
-
Q2 2024 revenue fell 10% year-over-year, with Advanced Energy sales down 17% but OEM sales up 29%. Handpiece sales grew over 20% globally, offsetting weak generator demand. 2024 guidance was updated, with revenue expected to be flat to down 3% and net loss guidance improved.